JP2024505723A5 - - Google Patents

Info

Publication number
JP2024505723A5
JP2024505723A5 JP2023547812A JP2023547812A JP2024505723A5 JP 2024505723 A5 JP2024505723 A5 JP 2024505723A5 JP 2023547812 A JP2023547812 A JP 2023547812A JP 2023547812 A JP2023547812 A JP 2023547812A JP 2024505723 A5 JP2024505723 A5 JP 2024505723A5
Authority
JP
Japan
Application number
JP2023547812A
Other languages
Japanese (ja)
Other versions
JPWO2022173667A5 (https=
JP2024505723A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US17/665,190 external-priority patent/US12233132B2/en
Publication of JP2024505723A publication Critical patent/JP2024505723A/ja
Publication of JPWO2022173667A5 publication Critical patent/JPWO2022173667A5/ja
Publication of JP2024505723A5 publication Critical patent/JP2024505723A5/ja
Pending legal-status Critical Current

Links

JP2023547812A 2021-02-09 2022-02-04 ポリオキサゾリン-脂質コンジュゲート並びにそれらを含む脂質ナノ粒子及び医薬組成物 Pending JP2024505723A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163147470P 2021-02-09 2021-02-09
US63/147,470 2021-02-09
US17/665,190 US12233132B2 (en) 2021-02-09 2022-02-04 Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
US17/665,190 2022-02-04
PCT/US2022/015314 WO2022173667A1 (en) 2021-02-09 2022-02-04 Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same

Publications (3)

Publication Number Publication Date
JP2024505723A JP2024505723A (ja) 2024-02-07
JPWO2022173667A5 JPWO2022173667A5 (https=) 2025-03-06
JP2024505723A5 true JP2024505723A5 (https=) 2025-03-06

Family

ID=82703446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547812A Pending JP2024505723A (ja) 2021-02-09 2022-02-04 ポリオキサゾリン-脂質コンジュゲート並びにそれらを含む脂質ナノ粒子及び医薬組成物

Country Status (9)

Country Link
US (2) US12233132B2 (https=)
EP (1) EP4291242A4 (https=)
JP (1) JP2024505723A (https=)
KR (1) KR20230144574A (https=)
CN (1) CN117098558A (https=)
AU (1) AU2022219902A1 (https=)
CA (1) CA3206128A1 (https=)
IL (1) IL304773A (https=)
WO (1) WO2022173667A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN118900701A (zh) * 2022-01-31 2024-11-05 盖纳万科学有限公司 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
AU2023425729A1 (en) * 2023-01-20 2025-07-17 Serina Therapeutics (Al), Inc. Targeting of antigen-presenting cells by nanoparticles containing polyoxazoline-lipid conjugates
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
IL324725A (en) * 2023-06-15 2026-01-01 Serina Therapeutics Al Inc Poly(oxazoline) conjugates with pendant cationic groups and lipid nanoparticles and polyplexes comprising them
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025137256A1 (en) * 2023-12-20 2025-06-26 Wu Nian Polyoxazoline-carbohydrate-lipid conjugates
WO2025134071A1 (en) 2023-12-22 2025-06-26 Sanofi Malic and glutaric acid based ionizable lipids
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
WO2025257084A1 (en) * 2024-06-10 2025-12-18 Isar Bioscience Gmbh Lipid composition
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026053147A1 (en) 2024-09-05 2026-03-12 Sanofi Pasteur Inc. Helper lipids and lnp compositions comprising same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JP2602544B2 (ja) * 1989-03-20 1997-04-23 花王株式会社 新規オリゴマー、その製法および用途
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
JPH08286313A (ja) * 1995-04-14 1996-11-01 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
US8088884B2 (en) 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5642673B2 (ja) * 2008-07-10 2014-12-17 セリナ・セラピユーテイツクス・インコーポレーテツド 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物
US20110313017A1 (en) * 2010-01-13 2011-12-22 Protiva Biotherapeutics, Inc. Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates
SG186085A1 (en) * 2010-06-03 2013-01-30 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
PT3970742T (pt) * 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
US12485181B2 (en) * 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties

Similar Documents

Publication Publication Date Title
JP2024505723A5 (https=)
JP2025504682A5 (https=)
CL2025003823A1 (es) Proceso para la extracción de magnesio metálico de fuentes de minerales.
BR202022005961U2 (https=)
BY13170U (https=)
BY13174U (https=)
CN307049130S (https=)
CN307047491S (https=)
CN307046925S (https=)
CN307046125S (https=)
CN307046040S (https=)
CN307045638S (https=)
CN307045542S (https=)
CN307045280S (https=)
CN307045004S (https=)
CN307044940S (https=)
CN307044649S (https=)
CN307044340S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13172U (https=)
BY13169U (https=)
BY13168U (https=)
BY13167U (https=)